PharmaCyte Biotech Inc (PMCB)

[Daphnis]

PMCB was given the licensing right to Austrianovas cell-in-a-box technology by Austrianova. PMCB was also given a 14.5% equity “stake” in Austrianova. (PMCB provided financing, etc.) PMCB has another 1.5 years to get shit done or lose the exclusive rights to the technology. Rights to the technology remains. The 14.5% interest in Austrianova remains. MY OPINION: PMCB has EVERYTHING set up and ready to go once the FDA’s list pertaining to the clinical hold is addressed. PMCB has significant value at this stage. Austrianova has been in the thick of things with PMCB for seven years. PMCB has 14.5% equity interest in Austrianova. PMCB will retain rights to use this technology regardless if its exclusive or not. PMCB has an incredibly in depth patent established with additional patent pending material surrounding further uses of the technology. Austrianova and PMCBs interests are linked across the board. They will continue to push forward together. MY GUESS: PMCB and Austrianova bring in a third party SPAC -go public- and get this technology to clinical trial ASAP. IMO there are massive gains to be had for investors regardless of what form PMCB takes following an agreement.